£76.38

Springer RNA Metabolism in Neurodegenerative Diseases: 20 (Advances in Neurobiology, 20)

Price data last checked 8 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

This is the most expensive it has ever been. Walk away.

£76 today · previous high £76 · all-time low £75

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 83 days · 83 data points (no recent data)

Historical
Generating forecast…
£76.38 £75.38 £75.60 £75.82 £76.03 £76.25 £76.47 09 May 2026 29 May 2026 19 June 2026 09 July 2026 30 July 2026

Price Distribution

Price distribution over 83 days • 2 price levels

Days at Price
Current Price
19 days 64 days · current 0 16 32 48 64 £75 £76 Days at Price

Price Analysis

Most common price: £76 (64 days, 77.1%)

Price range: £75 - £76

Price levels: 2 different prices over 83 days

Description

It has become evident over the last years that abnormalities in RNA processing play a fundamental part in the pathogenesis of neurodegenerative diseases. Cellular viability depends on proper regulation of RNA metabolism and subsequent protein synthesis, which requires the interplay of many processes including transcription, pre--‐mRNA splicing, mRNA editing as well as mRNA stability, transport and translation. Dysfunction in any of these processes, often caused by mutations in the coding and non--‐ coding RNAs, can be very destructive to the cellular environment and consequently impair neural viability. The result of this RNA toxicity can lead to a toxic gain of function or a loss of function, depending  on the nature of the mutation. For example, in repeat expansion disorders, such as the newly discovered hexanucleotide repeat expansion in theC9orf72 gene found in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a toxic gain of function leads to the formation of RNA foci and the sequestration of RNA binding proteins (RBPs). This in return leads to a loss of function of those RBPs, which is hypothesized to play a significant part in the disease progression of ALS and FTD. Other toxicities arising from repeat expansions are the formation of RNA foci, bi--‐directional transcription and production of repeat associated non--‐ATG (RAN) translation products.This book will touch upon most of these disease mechanisms triggered by aberrant RNA metabolism and will therefore provide a broad perspective of the role of RNA processing and its dysfunction in a variety of neurodegenerative disorders, including ALS, FTD, Alzheimer’s disease, Huntington’s disease, spinal muscular atrophy, myotonic dystrophy and ataxias.  The proposed authors are leading scientists in the field and are expected to not only discuss their own work, but to be inclusive of historic as well as late breaking discoveries. The compiled chapters will therefore provide a unique collection of novel studies and hypotheses aimed to describe the consequences of altered RNA processing events and its newest molecular players and pathways.  From the Back Cover It has become evident over the last years that abnormalities in RNA processing play a fundamental part in the pathogenesis of neurodegenerative diseases. Cellular viability depends on proper regulation of RNA metabolism and subsequent protein synthesis, which requires the interplay of many processes including transcription, pre‐mRNA splicing, mRNA editing as well as mRNA stability, transport and translation. Dysfunction in any of these processes, often caused by mutations in the coding and non‐coding RNAs, can be very destructive to the cellular environment and consequently impair neural viability. The result of this RNA toxicity can lead to a toxic gain of function or a loss of function, depending on the nature of the mutation. For example, in repeat expansion disorders, such as the newly discovered hexanucleotide repeat expansion in theC9orf72 gene found in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a toxic gain of function leads to the formation of RNA foci and the sequestration of RNA binding proteins (RBPs). This in return leads to a loss of function of those RBPs, which is hypothesized to play a significant part in the disease progression of ALS and FTD. Other toxicities arising from repeat expansions are the formation of RNA foci, bi‐directional transcription and production of repeat associated non‐ATG (RAN) translation products. This book will touch upon most of these disease mechanisms triggered by aberrant RNA metabolism and will therefore provide a broad perspective of the role of RNA processing and its dysfunction in a variety of neurodegenerative disorders, including ALS, FTD, Alzheimer’s disease, Huntington’s disease, spinal muscular atrophy, myotonic dystrophy and ataxias. The proposed authors are leading scientists in

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
19 January 2019
Listed Since
19 January 2019

Barcode

No barcode data available

Similar Products You Might Like

Neurodegenerative Diseases: Clinical Aspects, Molecular Genetics and Biomarkers
83% match

Neurodegenerative Diseases: Clinical Aspects, Molecular Genetics and Biomarkers

Springer

£117.61 31 Jul 2026
83% match

Epigenetics and miRNA in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications

Elsevier

£157.99 04 Aug 2026
Pathogenesis of Neurodegenerative Disorders (Contemporary Neuroscience)
83% match

Pathogenesis of Neurodegenerative Disorders (Contemporary Neuroscience)

Humana

£147.14 05 Aug 2026
Neurodegenerative Disorders: Loss of Function Through Gain of Function (Research and Perspectives in Alzheimer's Disease)
82% match

Neurodegenerative Disorders: Loss of Function Through Gain of Function (Research and Perspectives in Alzheimer's Disease)

Springer

£107.93 12 Jun 2026
Mitochondrial Dynamics and Neurodegeneration
82% match

Mitochondrial Dynamics and Neurodegeneration

Springer

£107.98 02 Jun 2026
RNA Editing: 20 (Nucleic Acids and Molecular Biology, 20)
81% match

RNA Editing: 20 (Nucleic Acids and Molecular Biology, 20)

Springer

£108.01 04 Aug 2026
Polyglutamine Disorders: 1049 (Advances in Experimental Medicine and Biology, 1049)
80% match

Polyglutamine Disorders: 1049 (Advances in Experimental Medicine and Biology, 1049)

Springer

£93.13 12 Jun 2026
The Proteasome in Neurodegeneration
80% match

The Proteasome in Neurodegeneration

Springer

£76.42 06 Aug 2026
Protein Misfolding and Human Diseases: Deciphering the Central Role of Pathological Aggregation
80% match

Protein Misfolding and Human Diseases: Deciphering the Central Role of Pathological Aggregation

Elsevier

£125.04 05 Aug 2026
Stem Cell-based Therapy for Neurodegenerative Diseases: 1266 (Advances in Experimental Medicine and Biology, 1266)
80% match

Stem Cell-based Therapy for Neurodegenerative Diseases: 1266 (Advances in Experimental Medicine and Biology, 1266)

Springer

£71.18 05 Jun 2026
Neuroprotection Methods and Protocols: 399 (Methods in Molecular Biology, 399)
80% match

Neuroprotection Methods and Protocols: 399 (Methods in Molecular Biology, 399)

Humana

£75.68 03 Jun 2026
Protein Degradation in Health and Disease: 29 (Progress in Molecular and Subcellular Biology, 29)
80% match

Protein Degradation in Health and Disease: 29 (Progress in Molecular and Subcellular Biology, 29)

Springer

£74.01 07 Aug 2026
Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future: 2 (Advances in Predictive, Preventive and Personalised Medicine, 2)
80% match

Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future: 2 (Advances in Predictive, Preventive and Personalised Medicine, 2)

Springer

£114.71 05 Aug 2026
Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future: 2 (Advances in Predictive, Preventive and Personalised Medicine, 2)
80% match

Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future: 2 (Advances in Predictive, Preventive and Personalised Medicine, 2)

Springer

£108.75 14 Jun 2026
RNA Technologies and Their Applications
80% match

RNA Technologies and Their Applications

Springer

£148.05 02 Jun 2026
Neurodegenerative Disorders: A Clinical Guide
79% match

Neurodegenerative Disorders: A Clinical Guide

Springer

£60.42 05 Aug 2026
DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases (RNA Technologies)
79% match

DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases (RNA Technologies)

Springer

£108.01 05 Aug 2026
Molecular and Cellular Mechanisms of Neuronal Plasticity: Basic and Clinical Implications: 446 (Advances in Experimental Medicine and Biology, 446)
79% match

Molecular and Cellular Mechanisms of Neuronal Plasticity: Basic and Clinical Implications: 446 (Advances in Experimental Medicine and Biology, 446)

Springer

£108.01 06 Aug 2026
RNA Therapeutics: Function, Design, and Delivery: 629 (Methods in Molecular Biology, 629)
79% match

RNA Therapeutics: Function, Design, and Delivery: 629 (Methods in Molecular Biology, 629)

Humana

£81.74 06 Aug 2026
Alzheimer's Disease: Advances in Genetics, Molecular and Cellular Biology
79% match

Alzheimer's Disease: Advances in Genetics, Molecular and Cellular Biology

Springer

£108.01 06 Aug 2026
Advances in Genomics and Neurosciences for Neurologic and Behavioral Disorders
79% match

Advances in Genomics and Neurosciences for Neurologic and Behavioral Disorders

Academic Press

£145.99 04 Aug 2026
Neurodegenerative Diseases: 6 (Topics in Medicinal Chemistry, 6)
79% match

Neurodegenerative Diseases: 6 (Topics in Medicinal Chemistry, 6)

Springer

£108.01 05 Aug 2026
Brain Iron Metabolism and CNS Diseases: 1173 (Advances in Experimental Medicine and Biology, 1173)
79% match

Brain Iron Metabolism and CNS Diseases: 1173 (Advances in Experimental Medicine and Biology, 1173)

Springer

£76.42 04 Aug 2026
Programmed Cells from Basic Neuroscience to Therapy: 20 (Research and Perspectives in Neurosciences, 20)
79% match

Programmed Cells from Basic Neuroscience to Therapy: 20 (Research and Perspectives in Neurosciences, 20)

Springer

£106.91 11 Jun 2026